245 related articles for article (PubMed ID: 22864536)
1. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies.
Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
Support Care Cancer; 2013 Feb; 21(2):549-55. PubMed ID: 22864536
[TBL] [Abstract][Full Text] [Related]
2. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
Support Care Cancer; 2012 Oct; 20(10):2433-9. PubMed ID: 22231480
[TBL] [Abstract][Full Text] [Related]
3. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
4. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
Strasser F; Demmer R; Böhme C; Schmitz SF; Thuerlimann B; Cerny T; Gillessen S
Oncologist; 2008 Mar; 13(3):337-46. PubMed ID: 18378545
[TBL] [Abstract][Full Text] [Related]
5. Update on taxane development: new analogs and new formulations.
Yared JA; Tkaczuk KH
Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and docetaxel in the treatment of breast cancer.
Saloustros E; Mavroudis D; Georgoulias V
Expert Opin Pharmacother; 2008 Oct; 9(15):2603-16. PubMed ID: 18803448
[TBL] [Abstract][Full Text] [Related]
7. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
8. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Schwartzberg LS; Cobb P; Walker MS; Stepanski EJ; Houts AC
Support Care Cancer; 2009 Aug; 17(8):1081-8. PubMed ID: 19148686
[TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
10. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
Bellon JR; Lindsley KL; Ellis GK; Gralow JR; Livingston RB; Austin Seymour MM
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):393-7. PubMed ID: 10974452
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
13. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
15. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
16. [Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
Schneeweiss A; Lenz F; Beldermann F; Geberth M; Goerner R; Solomayer E; Bastert G
Zentralbl Gynakol; 2001 Sep; 123(9):520-8. PubMed ID: 11709745
[TBL] [Abstract][Full Text] [Related]
17. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
[TBL] [Abstract][Full Text] [Related]
18. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
[TBL] [Abstract][Full Text] [Related]
19. Taxanes in elderly breast cancer patients.
Wildiers H; Paridaens R
Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
[TBL] [Abstract][Full Text] [Related]
20. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
Langer-Nitsche C; Lück HJ; Heilmann M
Acta Oncol; 2000; 39(8):1001. PubMed ID: 11206991
[No Abstract] [Full Text] [Related]
[Next] [New Search]
